Vancouver, British Columbia – TheNewswire – October 14, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that Dr. Lahiru Russell from Digital Mind Technology has been appointed as a medical advisor to Blackhawk.
Dr. Russell, with over 10 years of experience in clinical trials and research in psycho-oncology, is developing a platform for mindfulness-based interventions to promote self-regulation of emotions and thoughts to reduce negative mental health conditions.
Dr. Russell has transferred all her relevant intellectual property to Digital Mind Technology including proven clinical tools (developed from clinical research with 69 patients diagnosed with advanced stage Melanoma), for actively engaging and treating patients to help cope with the negative mental health outcomes of their illness. MindBio currently has a commercialization agreement with Digital Mind Technology.
In addition, MindBio is planning to implement Google Cloud’s “Health Care Solutions” for its international clinical trials to better manage clinical trials and analysis of data for drug development.
Google has developed cloud solutions that can help accelerate drug development and clinical trials to bring therapies to patients faster. With the Food and Drug Administration’s (FDA) MyStudies Application integration, the Google Cloud uses mobile tools to recruit, enroll, and engage with patients, collecting data directly from participants in a regulatory-compliant manner.
MindBio’s partner, Digital Mind Technology, will provide consulting services to MindBio on best practices and implementation of the Google health solution. Digital Mind Technology, run by Dr. Lahiru Russel, has used Google’s health solutions extensively in her clinical trials and PhD. The intellectual property and knowledge of these trials have been transferred to Digital Mind where she is now building a platform for mindfulness interventions to promote self-regulation of emotions and thoughts that lead to a reduction in mental health conditions.
“Dr. Russell is a welcome addition to our team” said Frederick Pels, CEO of Blackhawk Growth Corp. “Her experience will be a relied upon asset for MindBio, Leichtmind and Trip Pharma. I look forward to updating shareholders with our progress as we continue to grow our life science initiative.”
About Blackhawk Growth
Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.
The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.
For further information please contact:
Frederick Pels, Chief Executive Officer
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.